The Patent Finder
TL

Tiziana Life Sciences PLC

First filing 2017
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Four patents currently held, every record listed here

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Sep 2037. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Sep 2037
Next term end
3
Patent families

When these terms end

Each bar runs from grant to computed term end. 2020 to 2038.
US 10,973,773 Dactinomycin Compositions and Methods for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia Sep 13, 2037
US 11,975,111 Dactinomycin Compositions and Methods for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia Sep 13, 2037
US 10,688,186 ANTI-CD3 Antibody Formulations Oct 20, 2037
US 10,758,541 Formulations of Milciclib and Therapeutic Combinations of the Same for Use in the Treatment of Cancer Nov 6, 2038
20242028203220362038
10 pending applications: term is not computable until grant.Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 7, 2027
    The maintenance fee for Dactinomycin Compositions and Methods for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia (US 11,975,111) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 4 of 4

PatentTitleStatusExpiresConfidence
US 10,973,773Dactinomycin Compositions and Methods for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia
In force
 · High confidence
In forceHigh confidence
US 11,975,111Dactinomycin Compositions and Methods for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia
In force
 · High confidence
In forceHigh confidence
US 10,688,186ANTI-CD3 Antibody Formulations
In force
 · High confidence
In forceHigh confidence
US 10,758,541Formulations of Milciclib and Therapeutic Combinations of the Same for Use in the Treatment of Cancer
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 4: 10 applications pending · 9 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited